Group 1 - The company announced the use of idle funds to subscribe to notes linked to a fund issued by Essence Global Investment Limited and China Rock Fund, with a total scale of approximately HKD 400 million, aimed at enhancing capital returns and ensuring liquidity [1] - Following the announcement, the company's stock price increased by 3.76% on the first trading day (February 9), but experienced volatility in subsequent days [1] - Over the five trading days from February 9 to February 13, the stock price showed fluctuations, with a maximum range of 10.16%, indicating mixed market sentiment [1] Group 2 - According to the Q2 2025 financial report, the company recorded a quarterly revenue of approximately CNY 159 million, a quarter-on-quarter increase of 76.7%, and a net profit of CNY 52 million, with a gross margin of 84% [2] - The generic drug business accounted for 98% of the revenue, with centralized procurement products contributing significantly to the growth [2] - Although the financial report data is robust, its release in October 2025 means it has limited direct impact on the current stock price [2]

Core Viewpoint - HaiXi New Drug (02637) announced its investment strategy to utilize idle funds effectively by subscribing to structured notes and a fund, aiming to enhance capital returns while ensuring liquidity and meeting operational needs [1] Group 1: Investment Details - The company plans to invest HKD 200 million in structured notes issued by Essence Global Investment Limited under its USD 1 billion secured structured note program [1] - Additionally, the company will subscribe up to HKD 200 million in China Rock Fund SPC, collectively referred to as the subscription matters [1] Group 2: Financial Strategy - The investment aligns with the company's core objective of improving capital returns while ensuring the safety and liquidity of funds [1] - The strategy also aims to meet the group's daily operational and dividend payment funding requirements [1]

智通财经APP讯，海西新药(02637)发布公告，于2025年10月24日，福建海西新药创制股份有限公司(本 公司)作为投资者，动用其闲置资金，认购(i)2亿港元由Essence Global Investment Limited根据其10亿美 元有担保结构性票据计划发行的2025-32系列基金挂钩票据(基金挂鈎票据)(认购基金挂钩票据);及(ii)最 多2亿港元的China Rock Fund SPC(认购China Rock Fund，连同认购基金挂钩票据称为认购事项)。 合理有效地利用临时闲置资金可提高本公司的资本收益，与本公司确保资金安全和流动性以及满足本集 团日常运营及股息派付的资金需求这一核心目标一致。 ...

Core Viewpoint - Hai Xi New Drug (02637.HK) announced its plan to utilize idle funds for investments in structured notes and a fund subscription, indicating a strategic move to enhance its investment portfolio [1] Group 1: Investment Details - The company will invest HKD 200 million in notes issued by Essence Global Investment Limited under its USD 1 billion secured structured note program [1] - Additionally, the company plans to subscribe up to HKD 200 million in the China Rock Fund SPC [1] - The total investment amount for the subscription matters is therefore up to HKD 400 million [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 本月底法定/註冊股本總額： RMB 78,707,270 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 致：香港交易及結算所有限公司 公司名稱: 福建海西新藥創制股份有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02637 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 78,707,270 | RMB | | 1 RMB | | 78,707,270 | | 增加 / 減少 (-) | | | | 0 | | RMB | | | | 本月底結存 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 Fujian Haixi Pharmaceuticals Co., Ltd. 福建海西新藥創制股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2637） 須予披露交易 認購金融產品 認購金融產品 董事會宣佈，於2025年10月24日，福建海西新藥創制股份有限公司（「本公司」）作 為投資者，動用其閒置資金，認購(i)200,000,000港元由Essence Global Investment Limited根據其1,000,000,000美元有擔保結構性票據計劃發行的2025-32系列基金 掛鈎票據（「基金掛鈎票據」）（「認購基金掛鈎票據」）；及(ii)最多200,000,000港元的 China Rock Fund SPC（「認購China Rock Fund」，連同認購基金掛鈎票據稱為「認 購事項」）。 認購事項的主要條款載列如下： A. 認購基金掛鈎票據 「基金回報金額」指發 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 第 1 頁 共 10 頁 v 1.1.1 致：香港交易及結算所有限公司 公司名稱: 福建海西新藥創制股份有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02637 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 78,707,270 | RMB | | 1 RMB | | 78,707,270 | | 增加 / 減少 (-) | | | | 0 | | RMB | | | | 本月底結存 | | | 78,707,270 | RMB | | 1 RMB | | 78,707,270 | 本月底法定/註冊股本總額： ...

Group 1 - The stock of Haixi New Drug (02637.HK) experienced a significant increase, rising over 7% at one point and currently up by 6.1%, trading at 140.9 HKD [2] - The trading volume reached 15.9455 million HKD, indicating active market participation [2] - The company's total market capitalization has surpassed 11 billion HKD [2]

Core Viewpoint - Haixi New Drug (02637) experienced a significant stock price increase, rising over 7% in early trading and currently up by 5.87%, with a market capitalization exceeding HKD 11 billion [1] Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company that integrates research and development, production, and sales capabilities [1] - The company has 15 approved generic drug products covering various therapeutic areas, including the digestive system, cardiovascular system, endocrine system, and nervous system [1] - Haixi New Drug has established a pipeline of four innovative drugs under development, targeting cancer, ophthalmology, and respiratory diseases [1] Market Performance - The current average daily market capitalization of Haixi New Drug is HKD 9.94 billion, which exceeds the threshold requirement for Hong Kong Stock Connect [1]

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Haixi Pharmaceutical, which rose over 7% and is currently trading at 140.9 HKD, with a market capitalization exceeding 11 billion HKD [1] - Haixi Pharmaceutical is a commercial-stage pharmaceutical company that integrates research, production, and sales capabilities, with a pipeline of innovative drugs under development [1] - As of the date of the prospectus disclosure, Haixi Pharmaceutical has received approval for 15 generic drug products, covering various therapeutic areas including the digestive system, cardiovascular system, endocrine system, and nervous system [1] Group 2 - The company has established a pipeline of four innovative drugs currently under development, targeting diseases in oncology, ophthalmology, and respiratory systems [1] - The average daily market capitalization of Haixi Pharmaceutical has reached 99.4 billion HKD, which is above the threshold required for Hong Kong Stock Connect [1]